Abstract
Glioblastomas are characterized by a variety of genetic and epigenetic disorders, identification of which allows constantly expanding a list of genes directly involved in carcinogenesis, thus increasing molecular diagnostics, monitoring and predicting disease. Molecular-genetic studies of patients with glioblastomas allowed revealing changes relevant to this disease and determining their prognostic significance. In the future molecular-biological markers along with clinical and therapeutic factors may play a role of separate and independent factors of prognosis in patients with malignant brain lesions.
MeSH terms
-
Biomarkers, Tumor / genetics*
-
Carcinogenesis / genetics*
-
DNA Modification Methylases / genetics
-
DNA Mutational Analysis
-
DNA Repair Enzymes / genetics
-
Disease-Free Survival
-
ErbB Receptors / genetics
-
Female
-
Glioblastoma / epidemiology
-
Glioblastoma / genetics*
-
Glioblastoma / pathology
-
Humans
-
Isocitrate Dehydrogenase / genetics
-
Male
-
Middle Aged
-
Peroxiredoxins / genetics
-
Prognosis*
-
Promoter Regions, Genetic
-
Tumor Suppressor Proteins / genetics
Substances
-
Biomarkers, Tumor
-
Tumor Suppressor Proteins
-
IDH2 protein, human
-
Isocitrate Dehydrogenase
-
IDH1 protein, human
-
PRDX1 protein, human
-
Peroxiredoxins
-
DNA Modification Methylases
-
MGMT protein, human
-
EGFR protein, human
-
ErbB Receptors
-
DNA Repair Enzymes